内科理论与实践2025，Vol.20Issue(2)：101-106,6.DOI:10.16138/j.1673-6087.2025.02.01
炎症性肠病患者缓解期药物降级策略
Medicine de-escalation strategies in inflammatory bowel disease for remission maintenance
摘要
Abstract
Inflammatory bowel disease(IBD),including ulcerative colitis(UC)and Crohn disease(CD),requires long-term medication to maintain remission.Developing a medicine de-escalation strategies during remission is crucial for reducing side effects and alleviating economic burdens,but the risks and benefits of medicine discontinuation remain controversial.The dose of 5-aminosalicylic acid(5-ASA)can be reduced in partial UC patients during remission,but the risk of relapse increases after medicine discontinuation.Long-term use of immunomodulators such as azathioprine has safety issues,but safe discontinuation of the medicine can be achieved through a medicine monitoring systems.The relapse rate after discontinuation of biologics agents during remission is high,especially in patients who have not achieved deep remission.The medicine de-escalation strategy for patient receiving combination therapy requires comprehensive assessment.Relapse monitoring after medicine discontinuation is critical,endoscopy and biomarkers such as C-reactive protein(CRP)and fecal calprotectin(FCP)can be used as effective predictive tools.This review summarizes recent studies on medicine de-escalation in IBD remission to provide reference for clinical practice and promote shared decision-making between patients and physicians.关键词
炎症性肠病/药物降级/缓解期/复发监测Key words
Inflammatory bowel disease/Medicine de-escalation/Remission period/Recurrence monitoring分类
医药卫生引用本文复制引用
顾于蓓,洪聿..炎症性肠病患者缓解期药物降级策略[J].内科理论与实践,2025,20(2):101-106,6.基金项目
爱在延长炎症性肠病基金会青峰科研资助项目(CCCF-QF-2023) （CCCF-QF-2023）
